NURS 4430 Week 7 Therapy for Patients With Schizophrenia
According to the Schizophrenia and Related Disorders Alliance of America, approximately 3.5 million people in the United States are diagnosed with schizophrenia (n.d.), and it is one of the leading causes of disability. In practice, patients may present with delusions, hallucinations, disorganized thinking, disorganized or abnormal motor behavior, as well as other negative symptoms that can be disabling for these individuals.
Not only are these symptoms one of the most challenging symptom clusters you will encounter, many are associated with other disorders, such as depression, bipolar disorder, and disorders on the schizophrenia spectrum. As a psychiatric nurse practitioner, you must understand the underlying neurobiology of these symptoms to select appropriate therapies and improve outcomes for patients.
This week, as you examine antipsychotic therapies, you explore the assessment and treatment of patients with psychosis and schizophrenia. You also consider the ethical and legal implications of these therapies.
Reference:
- Schizophrenia and Related Disorders Alliance of America. (n.d.). About schizophrenia. https://sardaa.org/resources/about-schizophrenia/#:~:text=Quick%20Facts%20About%20Schizophrenia.%20Schizophrenia%20can%20be%20found,is%20one%20of%20the%20leading%20causes%20of%20disability
Learning Objectives
Students will:
- Assess client factors and history to develop personalized therapy plans for patients with insomnia
- Analyze factors that influence pharmacokinetic and pharmacodynamic processes in patients requiring therapy for insomnia
- Assess patient factors and history to develop personalized plans of antipsychotic therapy for patients
- Analyze factors that influence pharmacokinetic and pharmacodynamic processes in patients requiring antipsychotic therapy
- Synthesize knowledge of providing care to patients presenting for antipsychotic therapy
- Analyze ethical and legal implications related to prescribing antipsychotic therapy to patients across the lifespan
Learning Resources
- Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics (pp. 72–85). Elsevier.
- American Psychiatric Association. (2019). Practice guidelines for the treatment of patients with schizophrenia.https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Clinical%20Prac tice%20Guidelines/APA-Draft-Schizophrenia-Treatment-Guideline.pdf
- Clozapine REMS. (2015). Clozapine REMS: The single shared system for clozapine. https://www.clozapinerems.com/CpmgClozapineUI/rems/pdf/resources/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf
Medication Resources
- IBM Corporation. (2020). IBM Micromedex. https://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deepLink&institution=SZMC%5ESZMC%5ET43537
Note: To access the following medications, use the IBM Micromedex resource. Type the name of each medication in the keyword search bar. Be sure to read all sections on the left navigation bar related to each medication’s result page, as this information will be helpful for your review in preparation for your Assignments.
- amisulpride
- aripiprazole
- asenapine
- brexpiprazole
- cariprazine
- chlorpromazine
- clozapine
- lurasidone
- olanzapine
- paliperidone
- perphenazine
- pimavanserin
- quetiapine
- risperidone
Required Media
Case study: Pakistani woman with delusional thought processes
Note: This case study will serve as the foundation for this week’s Assignment.
Optional Resources
- Chakos, M., Patel, J. K., Rosenheck, R., Glick, I. D., Hammer, M. B., Tapp, A., Miller, A. L., & Miller, D. D. (2011). Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study. Clinical Schizophrenia & Related Psychoses, 5(3), 124–134.https://doi.org/10.3371/CSRP.5.3.2
- Fangfang, S., Stock, E. M., Copeland, L. A., Zeber, J. E., Ahmedani, B. K., & Morissette, S. B. (2014). Polypharmacy with antipsychotic drugs in patients with schizophrenia: Trends in multiple health care systems. American Journal of Health-System Pharmacy, 71(9), 728–738. https://doi.org/10.2146/ajhp130471
- Lin, L. A., Rosenheck, R., Sugar, C., & Zbrozek, A. (2015). Comparing antipsychotic treatments for schizophrenia: A health state approach. The Psychiatric Quarterly, 86(1), 107–121. https://doi.org/10.1007/s11126-014-9326
